

**ALPHA NPCR/ASCR V25 REQUIRED DATA ITEMS
KEY CODE RECOMMENDATIONS END OF REPORT**

Data Item Number	Data Item Name	Length	Source of Standard	Year Implemented	Version Implemented	NPCR Collect
570	Abstracted By	3	CoC			.
550	Accession Number--Hosp	9	CoC			.
70	Addr at DX--City	50	CoC			R
102	Addr at DX--Country	3	NAACCR	2013	13	.
2330	Addr at DX--No & Street	60	SEER			R
100	Addr at DX--Postal Code	9	CoC			R
80	Addr at DX--State	2	CoC	2011	12.2	R
2335	Addr at DX--Supplementl	60	SEER	2003	10	R
1810	Addr Current--City	50	SEER			.
1832	Addr Current--Country	3	NAACCR	2013	13	.
2350	Addr Current--No & Street	60	SEER			.
1830	Addr Current--Postal Code	9	SEER			.
1820	Addr Current--State	2	SEER			.
2355	Addr Current--Supplementl	60	SEER	2003	10	.
3803	Adenoid Cystic Basaloid Pattern	5	NAACCR			.
3804	Adenopathy	1	NAACCR	2018	18	.
3805	AFP Post-Orchiectomy Lab Value	7	NAACCR	2018	18	.
3806	AFP Post-Orchiectomy Range	1	NAACCR	2018	18	.
3807	AFP Pre-Orchiectomy Lab Value	7	NAACCR	2018	18	.
3808	AFP Pre-Orchiectomy Range	1	NAACCR	2018	18	.
3809	AFP Pretreatment Interpretation	1	NAACCR	2018	18	.
3810	AFP Pretreatment Lab Value	6	NAACCR	2018	18	.
230	Age at Diagnosis	3	SEER/CoC			R
2156	AJCC API Version Current	8	AJCC	2021	21	.
2157	AJCC API Version Original	8	AJCC	2021	21	.
2158	AJCC Cancer Surveillance DLL Version Current	13	AJCC	2021	21	D
2159	AJCC Cancer Surveillance DLL Version Original	13	AJCC	2021	21	D
995	AJCC ID	4	NAACCR	2018	18	D
1003	AJCC TNM Clin M	15	AJCC	2018	18	.
1002	AJCC TNM Clin N	15	AJCC	2018	18	.
1034	AJCC TNM Clin N Suffix	4	AJCC			.
1004	AJCC TNM Clin Stage Group	15	AJCC	2018	18	.
1001	AJCC TNM Clin T	15	AJCC	2018	18	.
1031	AJCC TNM Clin T Suffix	4	AJCC	2018	18	.
1013	AJCC TNM Path M	15	AJCC	2018	18	.
1012	AJCC TNM Path N	15	AJCC	2018	18	.
1035	AJCC TNM Path N Suffix	4	AJCC	2018	18	.
1014	AJCC TNM Path Stage Group	15	AJCC	2018	18	.
1011	AJCC TNM Path T	15	AJCC	2018	18	.
1032	AJCC TNM Path T Suffix	4	AJCC			.
1066	AJCC TNM Post Therapy Clin (yc) M	15	AJCC	2021	21	.
1064	AJCC TNM Post Therapy Clin (yc) N	15	AJCC	2021	21	.
1065	AJCC TNM Post Therapy Clin (yc) N Suffix	4	AJCC	2021	21	.
1067	AJCC TNM Post Therapy Clin (yc) Stage Group	15	AJCC	2021	21	.
1062	AJCC TNM Post Therapy Clin (yc) T	15	AJCC	2021	21	.
1063	AJCC TNM Post Therapy Clin (yc) T Suffix	4	AJCC	2021	21	.
1023	AJCC TNM Post Therapy Path (yp) M	15	AJCC	2018	18	.
1022	AJCC TNM Post Therapy Path (yp) N	15	AJCC	2018	18	.
1036	AJCC TNM Post Therapy Path (yp) N Suffix	4	AJCC	2018	18	.
1024	AJCC TNM Post Therapy Path (yp) Stage Group	15	AJCC	2018	18	.
1021	AJCC TNM Post Therapy Path (yp) T	15	AJCC	2018	18	.
1033	AJCC TNM Post Therapy Path (yp) T Suffix	4	AJCC	2018	18	.
3938	ALK Rearrangement	1	NAACCR	2021	21	.
442	Ambiguous Terminology DX	1	SEER	2006	11	.
3811	Anemia	1	NAACCR	2018	18	.
3100	Archive FIN	10	CoC	2003	10	.
1930	Autopsy	1	NAACCR			.
3812	B symptoms	1	NAACCR	2018	18	.
1972	Behavior (73-91) ICD-O-1	1	SEER			.
430	Behavior (92-00) ICD-O-2	1	SEER/CoC			RH
523	Behavior Code ICD-O-3	1	SEER/CoC	2001	9	R
3813	Bilirubin Pretreatment Total Lab Value	5	NAACCR	2018	18	.
3814	Bilirubin Pretreatment Unit of Measure	1	NAACCR	2018	18	.
254	Birthplace--Country	3	NAACCR	2013	13	R*
252	Birthplace--State	2	NAACCR	2013	13	R*
3815	Bone Invasion	1	NAACCR	2018	18	.
3940	BRAF Mutational Analysis	1	NAACCR	2021	21	.

3816	Brain Molecular Markers	2	NAACCR	2018	18	RS
3964	Brain Primary Tumor Location	1	SEER	2024	24	RS
3817	Breslow Tumor Thickness	4	NAACCR	2018	18	RS
3942	CA 19-9 PreTX Lab Value	6	NAACCR	2021	21	.
3818	CA-125 Pretreatment Interpretation	1	NAACCR	2018	18	.
1770	Cancer Status	1	CoC			.
501	Casefinding Source	2	NAACCR	2006	11	R*
1910	Cause of Death	4	SEER			R
3819	CEA Pretreatment Interpretation	1	NAACCR	2018	18	.
3820	CEA Pretreatment Lab Value	6	NAACCR	2018	18	.
362	Census Block Group 2000	1	Census			.
363	Census Block Group 2010	1	Census	2011	12.1	.
361	Census Block Group 2020	1	Census	2018	18	.
368	Census Block Grp 1970/80/90	1	Census	2008	11.2	.
120	Census Cod Sys 1970/80/90	1	SEER			RH*
272	Census Ind Code CDC	4	Census/NPCR	2013	13	R*
282	Census Occ Code CDC	4	Census/NPCR	2013	13	R*
364	Census Tr Cert 1970/80/90	1	SEER	1997	5.1	RH*
365	Census Tr Certainty 2000	1	NAACCR	2003	10	RH
367	Census Tr Certainty 2010	1	NAACCR	2011	12.1	R
145	Census Tr Poverty Indict	1	NAACCR	2013	13	D
110	Census Tract 1970/80/90	6	SEER			RH*
130	Census Tract 2000	6	NAACCR			RH
135	Census Tract 2010	6	NAACCR	2011	12.1	R
125	Census Tract 2020	6	NAACCR	2018	18	D
369	Census Tract Certainty 2020	1	NAACCR	2018	18	D
1189	Chromosome 16q: Loss of Heterozygosity	1	NAACCR/SEER	2025	25	.
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	1	NAACCR	2018	18	.
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	1	NAACCR	2018	18	.
1190	Chromosome 1q Status	1	NAACCR/SEER	2025	25	.
3821	Chromosome 3 Status	1	NAACCR	2018	18	.
3822	Chromosome 8q Status	1	NAACCR	2018	18	.
3823	Circumferential Resection Margin (CRM)	4	NAACCR	2018	18	.
610	Class of Case	2	CoC	1990	pre V4	R
3961	Clinical Margin Width	4	CoC	2023	2023	.
2152	CoC Accredited Flag	1	NPCR	2018	18	R
2140	CoC Coding Sys--Current	2	CoC			.
2150	CoC Coding Sys--Original	2	CoC			.
870	Coding System for EOD	1	SEER	1995	5	.
3110	Comorbid/Complication 1	5	CoC	2003	10	.
3164	Comorbid/Complication 10	5	CoC	2006	11	.
3120	Comorbid/Complication 2	5	CoC	2003	10	.
3130	Comorbid/Complication 3	5	CoC	2003	10	.
3140	Comorbid/Complication 4	5	CoC	2003	10	.
3150	Comorbid/Complication 5	5	CoC	2003	10	.
3160	Comorbid/Complication 6	5	CoC	2003	10	.
3161	Comorbid/Complication 7	5	CoC	2006	11	.
3162	Comorbid/Complication 8	5	CoC	2006	11	.
3163	Comorbid/Complication 9	5	CoC	2006	11	.
200	Computed Ethnicity	1	SEER	1995	4	.
210	Computed Ethnicity Source	1	SEER			.
89	County at DX Analysis	3	NAACCR	2018	18	D
94	County at DX Geocode 1970/80/90	3	NAACCR	2016	16	RH*
95	County at DX Geocode2000	3	NAACCR	2016	16	D
96	County at DX Geocode2010	3	NAACCR	2016	16	D
97	County at DX Geocode2020	3	NAACCR	2016	16	D
90	County at DX Reported	3	FIPS/SEER			R
1840	County--Current	3	NAACCR			.
3824	Creatinine Pretreatment Lab Value	4	NAACCR	2018	18	.
3825	Creatinine Pretreatment Unit of Measure	1	NAACCR	2018	18	.
2810	CS Extension	3	AJCC	2003	10	RH*
2830	CS Lymph Nodes	3	AJCC	2003	10	RH*
2840	CS Lymph Nodes Eval	1	AJCC			RH*
2850	CS Mets at DX	2	AJCC	2003	10	RH*
2851	CS Mets at Dx-Bone	1	AJCC	2010	12	.
2852	CS Mets at Dx-Brain	1	AJCC	2010	12	.
2853	CS Mets at Dx-Liver	1	AJCC	2010	12	.
2854	CS Mets at Dx-Lung	1	AJCC	2010	12	.
2860	CS Mets Eval	1	AJCC	2003	10	RH*
2880	CS Site-Specific Factor 1	3	AJCC	2003	10	RH*
2890	CS Site-Specific Factor 2	3	AJCC	2003	10	RH*
2900	CS Site-Specific Factor 3	3	AJCC	2003	10	RH*

2910	CS Site-Specific Factor 4	3	AJCC	2003	10	RH*
2920	CS Site-Specific Factor 5	3	AJCC	2003	10	RH*
2930	CS Site-Specific Factor 6	3	AJCC	2003	10	RH*
2861	CS Site-Specific Factor 7	3	AJCC	2010	12	RH*
2862	CS Site-Specific Factor 8	3	AJCC	2010	12	RH*
2863	CS Site-Specific Factor 9	3	AJCC	2010	12	RH*
2864	CS Site-Specific Factor10	3	AJCC	2010	12	RH*
2865	CS Site-Specific Factor11	3	AJCC	2010	12	RH*
2866	CS Site-Specific Factor12	3	AJCC	2010	12	RH*
2867	CS Site-Specific Factor13	3	AJCC	2010	12	RH*
2868	CS Site-Specific Factor14	3	AJCC	2010	12	RH*
2869	CS Site-Specific Factor15	3	AJCC	2010	12	RH*
2870	CS Site-Specific Factor16	3	AJCC	2010	12	RH*
2871	CS Site-Specific Factor17	3	AJCC	2010	12	RH*
2872	CS Site-Specific Factor18	3	AJCC	2010	12	.
2873	CS Site-Specific Factor19	3	AJCC	2010	12	.
2874	CS Site-Specific Factor20	3	AJCC	2010	12	.
2875	CS Site-Specific Factor21	3	AJCC	2010	12	.
2876	CS Site-Specific Factor22	3	AJCC	2010	12	.
2877	CS Site-Specific Factor23	3	AJCC	2010	12	.
2878	CS Site-Specific Factor24	3	AJCC	2010	12	.
2879	CS Site-Specific Factor25	3	AJCC	2010	12	RH*
2800	CS Tumor Size	3	AJCC	2003	10	RH*
2820	CS Tumor Size/Ext Eval	1	AJCC	2003	10	RH*
2936	CS Version Derived	6	AJCC			RH*
2937	CS Version Input Current	6	AJCC	2010	12	R*
2935	CS Version Input Original	6	AJCC			R*
1270	Date 1st Crs RX CoC	8	CoC			R#*
2090	Date Case Completed	8	NAACCR			.
2092	Date Case Completed--CoC	8	CoC	2010	12	.
2085	Date Case Initiated	8	NAACCR	2010	12	.
2100	Date Case Last Changed	8	NAACCR			.
2110	Date Case Report Exported	8	NPCR			R
2112	Date Case Report Loaded	8	NPCR	1997	5.1	R
2111	Date Case Report Received	8	NPCR	1997	5.1	R
443	Date Conclusive DX	8	SEER	2006	11	.
1260	Date Initial RX SEER	8	SEER			R#*
580	Date of 1st Contact	8	CoC			R*
240	Date of Birth	8	SEER/CoC			R
1755	Date of Death--Canada	8	CCCR	2009	11.3	.
390	Date of Diagnosis	8	SEER/CoC			R
590	Date of Inpt Adm	8	NAACCR			.
600	Date of Inpt Disch	8	NAACCR			.
1772	Date of Last Cancer (tumor) Status	8	CoC	2018	18	.
1750	Date of Last Contact	8	SEER/CoC			R
445	Date of Mult Tumors	8	SEER	2006	11	.
832	Date of Sentinel Lymph Node Biopsy	8	CoC	2018	18	.
682	Date Regional Lymph Node Dissection	8	NAACCR	2018	18	.
2113	Date Tumor Record Availbl	8	NPCR	1997	5.1	R
2380	DC State File Number	12	State	2011	12.2	R
2980	Derived AJCC-6 M	2	AJCC	2003	10	.
2990	Derived AJCC-6 M Descript	1	AJCC			.
2960	Derived AJCC-6 N	2	AJCC	2003	10	.
2970	Derived AJCC-6 N Descript	1	AJCC	2003	10	.
3000	Derived AJCC-6 Stage Grp	2	AJCC	2003	10	.
2940	Derived AJCC-6 T	2	AJCC	2003	10	.
2950	Derived AJCC-6 T Descript	1	AJCC	2003	10	.
3420	Derived AJCC-7 M	3	AJCC	2010	12	RH*
3422	Derived AJCC-7 M Descript	1	AJCC	2010	12	RH*
3410	Derived AJCC-7 N	3	AJCC	2010	12	RH*
3412	Derived AJCC-7 N Descript	1	AJCC	2010	12	RH*
3430	Derived AJCC-7 Stage Grp	3	AJCC	2010	12	RH*
3400	Derived AJCC-7 T	3	AJCC	2010	12	RH*
3402	Derived AJCC-7 T Descript	1	AJCC	2010	12	RH*
3030	Derived AJCC--Flag	1	AJCC	2003	10	.
795	Derived EOD 2018 M	15	SEER	2018	18	.
815	Derived EOD 2018 N	15	SEER	2018	18	.
818	Derived EOD 2018 Stage Group	15	SEER	2018	18	.
785	Derived EOD 2018 T	15	SEER	2018	18	.
1144	Derived Pediatric M	3	NAACCR/SEER	2025	25	.
1143	Derived Pediatric N	3	NAACCR/SEER	2025	25	.
1145	Derived Pediatric Stage Group	3	NAACCR/SEER	2025	25	.

1142	Derived Pediatric T	3	NAACCR/SEER	2025	25	.
3955	Derived Rai Stage	1	NAACCR	2022	22	.
3610	Derived SEER Clin Stg Grp	5	SEER	2016	16	.
3626	Derived SEER Cmb M Src	1	SEER	2016	16	.
3624	Derived SEER Cmb N Src	1	SEER			.
3614	Derived SEER Cmb Stg Grp	5	SEER	2016	16	.
3622	Derived SEER Cmb T Src	1	SEER	2016	16	.
3620	Derived SEER Combined M	5	SEER	2016	16	.
3618	Derived SEER Combined N	5	SEER			.
3616	Derived SEER Combined T	5	SEER			.
3605	Derived SEER Path Stg Grp	5	SEER			.
3010	Derived SS1977	1	AJCC	2003	10	.
3040	Derived SS1977--Flag	1	AJCC	2003	10	.
3020	Derived SS2000	1	AJCC	2003	10	RH*
3050	Derived SS2000--Flag	1	AJCC	2003	10	RH*
1975	Derived Summary Grade 2018	1	SEER	2024	24	D
762	Derived Summary Stage 2018	1	SEER	2018	16	.
490	Diagnostic Confirmation	1	SEER/CoC			R
531	EDP MDE Link	1	NPCR	2022	22	RS
530	EDP MDE Link Date	8	NPCR	2022	22	RS
3939	EGFR Mutational Analysis	1	NAACCR	2021	21	.
2508	EHR Reporting	4000	NAACCR	2018	18	.
776	EOD Mets	2	SEER	2018	16	.
772	EOD Primary Tumor	3	SEER	2018	16	.
3919	EOD Prostate Pathologic Extension	3	SEER	2018	18	.
774	EOD Regional Nodes	3	SEER	2018	16	.
790	EOD--Extension	2	SEER			.
800	EOD--Extension Prost Path	2	SEER	1995	4	.
810	EOD--Lymph Node Involv	1	SEER			.
840	EOD--Old 13 Digit	13	SEER			.
850	EOD--Old 2 Digit	2	SEER			.
860	EOD--Old 4 Digit	4	SEER			.
780	EOD--Tumor Size	3	SEER/CoC			.
3829	Esophagus and EGI Tumor Epicenter	1	NAACCR	2018	18	RS
3826	Estrogen Receptor Percent Positive or Range	3	NAACCR	2018	18	.
3827	Estrogen Receptor Summary	1	NAACCR	2018	18	RS
3828	Estrogen Receptor Total Allred Score	2	NAACCR	2018	18	.
1191	EWSR1-FLI1 fusion	1	NAACCR/SEER	2025	25	.
3830	Extranodal Extension Clin (non-Head and Neck)	1	NAACCR	2018	18	.
3831	Extranodal Extension Head and Neck Clinical	1	NAACCR	2018	18	.
3832	Extranodal Extension Head and Neck Pathological	3	NAACCR	2018	18	.
3833	Extranodal Extension Path (non-Head and Neck)	1	NAACCR	2018	18	.
3834	Extravascular Matrix Patterns	1	NAACCR	2018	18	.
3835	Fibrosis Score	1	NAACCR	2018	18	RS
3836	FIGO Stage	5	NAACCR	2018	18	.
2440	Following Registry	10	CoC			.
1842	Follow-Up Contact--City	50	SEER	1997	5.1	.
1847	FollowUp Contact--Country	3	NAACCR	2013	13	.
2394	Follow-Up Contact--Name	60	SEER	1997	5.1	.
2392	Follow-Up Contact--No&St	60	SEER	1997	5.1	.
1846	Follow-Up Contact--Postal	9	SEER	1997	5.1	.
1844	Follow-Up Contact--State	2	SEER	1997	5.1	.
2393	Follow-Up Contact--Suppl	60	SEER	2003	10	.
1790	Follow-Up Source	1	CoC			R*
1791	Follow-up Source Central	2	NAACCR	2006	11	R
1193	FOXO1 Gene Rearrangements	1	NAACCR/SEER	2025	25	.
86	Geocoding Quality Code	1	NAACCR	2024	24	D*
87	Geocoding Quality Code Detail	14	NAACCR	2024	24	D*
3837	Gestational Trophoblastic Prognostic Scoring Index	2	NAACCR	2018	18	.
366	GIS Coordinate Quality	2	NAACCR	2011	11	R*
3838	Gleason Patterns Clinical	2	NAACCR	2018	18	RS
3839	Gleason Patterns Pathological	2	NAACCR	2018	18	RS
3840	Gleason Score Clinical	2	NAACCR	2018	18	RS
3841	Gleason Score Pathological	2	NAACCR	2018	18	RS
3842	Gleason Tertiary Pattern	2	NAACCR	2018	18	RS*
440	Grade	1	SEER/CoC			RH
1973	Grade (73-91) ICD-O-1	1	SEER			.
3843	Grade Clinical	1	NAACCR	2018	18	R
449	Grade Path System	1	AJCC	2010	12	RH*
441	Grade Path Value	1	AJCC	2010	12	RH*
3844	Grade Pathological	1	NAACCR	2018	18	R
1068	Grade Post Therapy Clin (yc)	1	NAACCR	2021	21	R*

3845	Grade Post Therapy Path (yp)	1	NAACCR	2018	18	R*
3846	hCG Post-Orchiectomy Lab Value	7	NAACCR	2018	18	.
3847	hCG Post-Orchiectomy Range	1	NAACCR	2018	18	.
3848	hCG Pre-Orchiectomy Lab Value	7	NAACCR	2018	18	.
3849	hCG Pre-Orchiectomy Range	1	NAACCR	2018	18	.
3850	HER2 IHC Summary	1	NAACCR	2018	18	.
3851	HER2 ISH Dual Probe Copy Number	4	NAACCR	2018	18	.
3852	HER2 ISH Dual Probe Ratio	4	NAACCR	2018	18	.
3853	HER2 ISH Single Probe Copy Number	4	NAACCR	2018	18	.
3854	HER2 ISH Summary	1	NAACCR	2018	18	.
3855	HER2 Overall Summary	1	NAACCR	2018	18	RS
3856	Heritable Trait	1	NAACCR	2018	18	.
3857	High Risk Cytogenetics	1	NAACCR	2018	18	.
3858	High Risk Histologic Features	1	NAACCR			.
3960	Histologic Subtype	1	SEER	2023	23	RS*
522	Histologic Type ICD-O-3	4	SEER/CoC	2001	9	R
1971	Histology (73-91) ICD-O-1	4	SEER			.
420	Histology (92-00) ICD-O-2	4	SEER/CoC			RH
3859	HIV Status	1	NAACCR	2018	18	.
3165	ICD Revision Comorbid	1	CoC	2006	11	.
1920	ICD Revision Number	1	SEER			R
2116	ICD-O-3 Conversion Flag	1	SEER	2001	9	R
192	IHS Link	1	NPCR	2006	11	R*
194	IHS Purchased/Referred Care Delivery Area	1	NPCR	2022	22	D
300	Industry Source	1	NPCR			R*
2410	Institution Referred From	10	CoC			.
2420	Institution Referred To	10	CoC			.
3860	International Normalized Ratio Prothrombin Time	3	NAACCR	2018	18	.
1187	Intl Neuroblastoma Path Prog Class (INPC)	1	NAACCR/SEER	2025	25	.
1185	Intl Neuroblastoma Risk Grp Stag Sys (INRGSS)	1	NAACCR/SEER	2025	25	.
3864	Invasion Beyond Capsule	1	NAACCR	2018	18	.
3861	Ipsilateral Adrenal Gland Involvement	1	NAACCR	2018	18	.
1188	IRSS Stage for Eye-2	1	NAACCR/SEER	2025	25	.
3862	JAK2	1	NAACCR			.
3863	Ki-67	5	NAACCR	2018	18	.
3865	KIT Gene Immunohistochemistry	1	NAACCR	2018	18	.
3866	KRAS	1	NAACCR	2018	18	.
410	Laterality	1	SEER/CoC			R
2352	Latitude	10	NAACCR	2003	10	R*
3932	LDH Lab Value	7	NAACCR	2018	18	RS
3869	LDH Level	1	NAACCR			.
3867	LDH Post-Orchiectomy Range	1	NAACCR	2018	18	.
3868	LDH Pre-Orchiectomy Range	1	NAACCR	2018	18	.
3870	LDH Upper Limits of Normal	3	NAACCR	2018	18	.
3871	LN Assessment Method Femoral-Inguinal	1	NAACCR	2018	18	.
3872	LN Assessment Method Para-Aortic	1	NAACCR	2018	18	.
3873	LN Assessment Method Pelvic	1	NAACCR	2018	18	.
3874	LN Distant Assessment Method	1	NAACCR	2018	18	.
3875	LN Distant: Mediastinal, Scalene	1	NAACCR	2018	18	.
3876	LN Head and Neck Levels I-III	1	NAACCR			.
3877	LN Head and Neck Levels IV-V	1	NAACCR	2018	18	.
3878	LN Head and Neck Levels VI-VII	1	NAACCR	2018	18	.
3879	LN Head and Neck Other	1	NAACCR	2018	18	.
3880	LN Isolated Tumor Cells (ITC)	1	NAACCR	2018	18	.
3881	LN Laterality	1	NAACCR	2018	18	.
3882	LN Positive Axillary Level I-II	2	NAACCR	2018	18	.
3883	LN Size	4	NAACCR	2018	18	.
3959	LN Status Femoral-Inguinal	1	SEER	2022	22	.
3958	LN Status Para-Aortic	1	SEER	2022	22	.
3957	LN Status Pelvic	1	SEER	2022	22	.
2354	Longitude	11	NAACCR	2003	10	R*
3885	Lymphocytosis	1	NAACCR	2018	18	.
1182	Lymphovascular Invasion	1	AJCC	2010	12	R*
3950	Macroscopic Evaluation of Mesorectum	2	CoC	2022	22	.
3886	Major Vein Involvement	1	NAACCR	2018	18	.
150	Marital Status at DX	1	SEER			.
3887	Measured Basal Diameter	4	NAACCR	2018	18	.
3888	Measured Thickness	4	NAACCR	2018	18	.
2300	Medical Record Number	15	NAACCR			R
2315	Medicare Beneficiary Identifier	11	NAACCR	2018	18	R*
3889	Methylation of O6-Methylguanine-Methyltransferase	1	NAACCR			.
1112	Mets at DX-Bone	1	SEER	2016	16	.

1113	Mets at DX-Brain	1	SEER	2016	16	.
1114	Mets at Dx-Distant LN	1	SEER	2016	16	.
1115	Mets at DX-Liver	1	SEER	2016	16	.
1116	Mets at DX-Lung	1	SEER	2016	16	.
1117	Mets at DX-Other	1	SEER	2016	16	.
3890	Microsatellite Instability (MSI)	1	NAACCR	2018	18	RS*
3891	Microvascular Density	2	NAACCR	2018	18	.
3892	Mitotic Count Uveal Melanoma	4	NAACCR	2018	18	.
3893	Mitotic Rate Melanoma	2	NAACCR	2018	18	.
470	Morph Coding Sys--Current	1	NAACCR			R
480	Morph Coding Sys--Originl	1	NAACCR			.
444	Mult Tum Rpt as One Prim	2	SEER	2006	11	.
3894	Multigene Signature Method	1	NAACCR			.
3895	Multigene Signature Results	2	NAACCR	2018	18	.
446	Multiplicity Counter	2	SEER	2006	11	.
50	NAACCR Record Version	3	NAACCR			R
2280	Name--Alias	40	NAACCR			R
2232	Name--Birth Surname	40	NAACCR	2021	21	R
2240	Name--First	40	SEER	2011	12.2	R
2230	Name--Last	40	SEER	2011	12.2	R
2250	Name--Middle	40	SEER			R
2260	Name--Prefix	3	NAACCR	2011	12.2	.
2290	Name--Spouse/Parent	60	NAACCR	2011	12.2	.
2270	Name--Suffix	3	NAACCR	2011	12.2	.
3896	NCN International Prognostic Index (IPI)	2	NAACCR	2018	18	.
3946	NCDB--COVID19--Tx Impact	1	CoC	2021	21	.
3944	NCDB--SARSCoV2--Pos	1	CoC	2021	21	.
3945	NCDB--SARSCoV2--Pos Date	8	CoC	2021	21	.
3943	NCDB--SARSCoV2--Test	1	CoC	2021	21	.
1632	Neoadjuvant Therapy	1	SEER	2021	21	.
1633	Neoadjuvant Therapy-Clinical Response	1	SEER	2021	21	.
1634	Neoadjuvant Therapy-Treatment Effect	1	SEER	2021	21	.
1800	Next Follow-Up Source	1	CoC			.
191	NHIA Derived Hisp Origin	1	NAACCR	2005	10.2	D
1186	n-MYC Amplification	1	NAACCR/SEER	2025	25	.
1854	No Patient Contact Flag	1	NAACCR	2023	23	.
3645	NPCR Derived AJCC 8 TNM Clin Stg Grp	15	NPCR	2018	18	.
3646	NPCR Derived AJCC 8 TNM Path Stg Grp	15	NPCR	2018	18	.
3647	NPCR Derived AJCC 8 TNM Post Therapy Stg Grp	15	NPCR	2018	18	.
3720	NPCR Specific Field			2013	13	RH
3105	NPI--Archive FIN	10	CMS	2007	11.1	.
2445	NPI--Following Registry	10	CMS	2007	11.1	.
2415	NPI--Inst Referred From	10	CMS	2007	11.1	.
2425	NPI--Inst Referred To	10	CMS	2007	11.1	.
2495	NPI--Physician 3	10	CMS	2007	11.1	.
2505	NPI--Physician 4	10	CMS	2007	11.1	.
2475	NPI--Physician--Follow-Up	10	CMS	2007	11.1	.
2465	NPI--Physician--Managing	10	CMS	2007	11.1	.
2485	NPI--Physician--Primary Surg	10	CMS	2007	11.1	.
45	NPI--Registry ID	10	CMS	2007	11.1	.
545	NPI--Reporting Facility	10	CMS	2007	11.1	R*
3941	NRAS Mutational Analysis	1	NAACCR	2021	21	.
3897	Number of Cores Examined	2	NAACCR	2018	18	.
3898	Number of Cores Positive	2	NAACCR	2018	18	.
3899	Number of Examined Para-Aortic Nodes	2	NAACCR	2018	18	.
3900	Number of Examined Pelvic Nodes	2	NAACCR	2018	18	.
1532	Number of Phases of Rad Treatment to this Volume	2	CoC	2018	18	.
3901	Number of Positive Para-Aortic Nodes	2	NAACCR	2018	18	.
3902	Number of Positive Pelvic Nodes	2	NAACCR	2018	18	.
290	Occupation Source	1	NPCR			R*
3903	Oncotype Dx Recurrence Score-DCIS	3	NAACCR	2018	18	.
3904	Oncotype Dx Recurrence Score-Invasive	3	NAACCR	2018	18	.
3905	Oncotype Dx Risk Level-DCIS	1	NAACCR	2018	18	.
3906	Oncotype Dx Risk Level-Invasive	1	NAACCR	2018	18	.
3907	Organomegaly	1	NAACCR	2018	18	.
1985	Over-ride Acsn/Class/Seq	1	NAACCR	2001	9	.
1990	Over-ride Age/Site/Morph	1	SEER			R
1987	Over-ride CoC-Site/Type	1	NAACCR	2001	9	.
3750	Over-ride CS 1	1	AJCC	2011	12.1	.
3759	Over-ride CS 10	1	AJCC			.
3760	Over-ride CS 11	1	AJCC	2011	12.1	.
3761	Over-ride CS 12	1	AJCC			.

3762	Over-ride CS 13	1	AJCC	2011	12.1	.
3763	Over-ride CS 14	1	AJCC	2011	12.1	.
3764	Over-ride CS 15	1	AJCC	2011	12.1	.
3765	Over-ride CS 16	1	AJCC	2011	12.1	.
3766	Over-ride CS 17	1	AJCC	2011	12.1	.
3767	Over-ride CS 18	1	AJCC	2011	12.1	.
3768	Over-ride CS 19	1	AJCC	2011	12.1	.
3751	Over-ride CS 2	1	AJCC	2011	12.1	.
3769	Over-ride CS 20	1	AJCC/NPCR	2011	12.1	RH
3752	Over-ride CS 3	1	AJCC	2011	12.1	.
3753	Over-ride CS 4	1	AJCC	2011	12.1	.
3754	Over-ride CS 5	1	AJCC	2011	12.1	.
3755	Over-ride CS 6	1	AJCC	2011	12.1	.
3756	Over-ride CS 7	1	AJCC	2011	12.1	.
3757	Over-ride CS 8	1	AJCC	2011	12.1	.
3758	Over-ride CS 9	1	AJCC	2011	12.1	.
2040	Over-ride Histology	1	SEER			R
1986	Over-ride HospSeq/DxConf	1	NAACCR	2001	9	.
1988	Over-ride HospSeq/Site	1	NAACCR	2001	9	.
2060	Over-ride Ill-define Site	1	SEER			R
2070	Over-ride Leuk, Lymphoma	1	SEER			R
2078	Over-ride Name/Sex	1	NAACCR	2018	18	R
2050	Over-ride Report Source	1	SEER			R
2000	Over-ride SeqNo/DxConf	1	SEER			R
2071	Over-ride Site/Behavior	1	SEER	1997	5.1	R
2072	Over-ride Site/EOD/DX Dt	1	SEER	1997	5.1	.
2073	Over-ride Site/Lat/EOD	1	SEER	1997	5.1	.
2074	Over-ride Site/Lat/Morph	1	SEER	1997	5.1	R
2010	Over-ride Site/Lat/SeqNo	1	SEER			R
1989	Over-ride Site/TNM-StgGrp	1	NAACCR	2001	9	.
2030	Over-ride Site/Type	1	SEER			R
1981	Over-ride SS/NodesPos	1	NAACCR	2001	9	.
1983	Over-ride SS/TNM-M	1	NAACCR	2001	9	.
1982	Over-ride SS/TNM-N	1	NAACCR			.
2020	Over-ride Surg/DxConf	1	SEER			R
1994	Over-ride TNM 3	1	NAACCR	2018	18	.
1992	Over-ride TNM Stage	1	NAACCR	2018	18	.
1993	Over-ride TNM Tis	1	NAACCR	2018	18	.
3956	p16	1	SEER	2022	22	RS
7320	Path Date Spec Collect 1	25	HL7	2010	12	.
7321	Path Date Spec Collect 2	25	HL7	2010	12	.
7322	Path Date Spec Collect 3	25	HL7	2010	12	.
7323	Path Date Spec Collect 4	25	HL7	2010	12	.
7324	Path Date Spec Collect 5	25	HL7	2010	12	.
7100	Path Order Phys Lic No 1	20	HL7	2010	12	.
7101	Path Order Phys Lic No 2	20	HL7	2010	12	.
7102	Path Order Phys Lic No 3	20	HL7	2010	12	.
7103	Path Order Phys Lic No 4	20	HL7	2010	12	.
7104	Path Order Phys Lic No 5	20	HL7	2010	12	.
7190	Path Ordering Fac No 1	25	HL7	2010	12	.
7191	Path Ordering Fac No 2	25	HL7	2010	12	.
7192	Path Ordering Fac No 3	25	HL7	2010	12	.
7193	Path Ordering Fac No 4	25	HL7	2010	12	.
7194	Path Ordering Fac No 5	25	HL7	2010	12	.
7090	Path Report Number 1	20	HL7	2010	12	.
7091	Path Report Number 2	20	HL7	2010	12	.
7092	Path Report Number 3	20	HL7	2010	12	.
7093	Path Report Number 4	20	HL7	2010	12	.
7094	Path Report Number 5	20	HL7	2010	12	.
7480	Path Report Type 1	2	HL7	2010	12	.
7481	Path Report Type 2	2	HL7	2010	12	.
7482	Path Report Type 3	2	HL7	2010	12	.
7483	Path Report Type 4	2	HL7	2010	12	.
7484	Path Report Type 5	2	HL7	2010	12	.
7010	Path Reporting Fac ID 1	25	HL7	2010	12	.
7011	Path Reporting Fac ID 2	25	HL7			.
7012	Path Reporting Fac ID 3	25	HL7	2010	12	.
7013	Path Reporting Fac ID 4	25	HL7	2010	12	.
7014	Path Reporting Fac ID 5	25	HL7	2010	12	.
20	Patient ID Number	8	Reporting Registry			R
21	Patient System ID-Hosp	8	NAACCR	2006	11	.
1174	PD-L1	5	NAACCR	2025	25	RS*

1132	Pediatric ID	5	NAACCR	2025	25	.
1133	Pediatric ID Version Current	5	NAACCR/SEER	2025	25	.
1134	Pediatric ID Version Original	5	NAACCR/SEER	2025	25	.
1138	Pediatric Mets	2	NAACCR/SEER	2025	25	.
1136	Pediatric Primary Tumor	3	NAACCR/SEER	2025	25	.
1137	Pediatric Regional Nodes	3	NAACCR/SEER	2025	25	.
1120	Pediatric Stage	2	CoC			.
1140	Pediatric Staged By	1	CoC			.
1130	Pediatric Staging System	2	CoC			.
3908	Percent Necrosis Post Neoadjuvant	5	NAACCR	2018	18	.
3909	Perineural Invasion	1	NAACCR	2018	18	.
3910	Peripheral Blood Involvement	1	NAACCR	2018	18	.
3911	Peritoneal Cytology	1	NAACCR	2018	18	.
1501	Phase I Dose per Fraction	5	CoC	2018	18	.
1503	Phase I Number of Fractions	3	CoC	2018	18	.
1502	Phase I Radiation External Beam Planning Tech	2	CoC	2018	18	.
1504	Phase I Radiation Primary Treatment Volume	2	CoC	2018	18	.
1505	Phase I Radiation to Draining Lymph Nodes	2	CoC	2018	18	.
1506	Phase I Radiation Treatment Modality	2	CoC	2018	18	R
1507	Phase I Total Dose	6	CoC	2018	18	.
1511	Phase II Dose per Fraction	5	CoC	2018	18	.
1513	Phase II Number of Fractions	3	CoC	2018	18	.
1512	Phase II Radiation External Beam Planning Tech	2	CoC	2018	18	.
1514	Phase II Radiation Primary Treatment Volume	2	CoC	2018	18	.
1515	Phase II Radiation to Draining Lymph Nodes	2	CoC	2018	18	.
1516	Phase II Radiation Treatment Modality	2	CoC	2018	18	.
1517	Phase II Total Dose	6	CoC	2018	18	.
1521	Phase III Dose per Fraction	5	CoC	2018	18	.
1523	Phase III Number of Fractions	3	CoC	2018	18	.
1522	Phase III Radiation External Beam Planning Tech	2	CoC	2018	18	.
1524	Phase III Radiation Primary Treatment Volume	2	CoC	2018	18	.
1525	Phase III Radiation to Draining Lymph Nodes	2	CoC	2018	18	.
1526	Phase III Radiation Treatment Modality	2	CoC	2018	18	.
1527	Phase III Total Dose	6	CoC	2018	18	.
2490	Physician 3	8	CoC			.
2500	Physician 4	8	CoC			.
2470	Physician--Follow-Up	8	CoC			.
2460	Physician--Managing	8	NAACCR			.
2480	Physician--Primary Surg	8	CoC			.
1944	Place of Death--Country	3	NAACCR	2013	13	R*
1942	Place of Death--State	2	NAACCR	2013	13	R
3913	Pleural Effusion	1	NAACCR			.
1172	Post Transplant Lymphoproliferative Disorder-PTLD	1	NAACCR	2025	25	RS*
1192	Pretext Clinical Staging	1	NAACCR/SEER	2025	25	.
630	Primary Payer at DX	2	CoC			R*
3917	Primary Sclerosing Cholangitis	1	NAACCR	2018	18	.
400	Primary Site	4	SEER/CoC			R
3918	Profound Immune Suppression	1	NAACCR	2018	18	.
3914	Progesterone Receptor Percent Positive or Range	3	NAACCR	2018	18	.
3915	Progesterone Receptor Summary	1	NAACCR	2018	18	RS
3916	Progesterone Receptor Total Allred Score	2	NAACCR	2018	18	.
3920	PSA (Prostatic Specific Antigen) Lab Value	5	NAACCR	2018	18	RS
160	Race 1	2	SEER/CoC			R
161	Race 2	2	SEER			R
162	Race 3	2	SEER			R
163	Race 4	2	SEER			R
164	Race 5	2	SEER			R
193	Race--NAPIIA(derived API)	2	NAACCR	2009	11.3	R
1531	Radiation Treatment Discontinued Early	2	CoC	2018	18	.
1550	Rad--Location of RX	1	CoC			.
1570	Rad--Regional RX Modality	2	CoC			RH
3190	Readm Same Hosp 30 Days	1	CoC	2003	10	.
1430	Reason for No Radiation	1	CoC			R
1340	Reason for No Surgery	1	SEER/CoC			R
1775	Record Number Recode	2	NAACCR	2018	18	D
10	Record Type	1	NAACCR		pre V4	R
1860	Recurrence Date--1st	8	CoC			.
1880	Recurrence Type--1st	2	CoC			.
830	Regional Nodes Examined	2	SEER/CoC			R
820	Regional Nodes Positive	2	SEER/CoC			R
40	Registry ID	10	NAACCR			R
30	Registry Type	1	NAACCR			.

540	Reporting Facility	10	CoC			R
1856	Reporting Facility Restriction Flag	2	NAACCR	2023	23	.
3921	Residual Tumor Volume Post Cytoreduction	2	NAACCR	2018	18	.
3922	Response to Neoadjuvant Therapy	1	NAACCR	2018	18	.
339	RUCA 2000	1	NAACCR	2018	18	D
341	RUCA 2010	1	NAACCR	2018	18	D
3300	RuralUrban Continuum 1993	2	NAACCR	2003	10	D
3310	RuralUrban Continuum 2003	2	NAACCR	2003	10	D
3312	RuralUrban Continuum 2013	2	NAACCR	2016	16	D
1460	RX Coding System--Current	2	NAACCR			R
1240	RX Date BRM	8	CoC			R*
1220	RX Date Chemo	8	CoC			R*
1280	RX Date DX/Stg Proc	8	CoC			.
1230	RX Date Hormone	8	CoC			R*
3170	RX Date Mst Defn Srg	8	CoC	2003	10	R*
1250	RX Date Other	8	CoC			R*
3220	RX Date Rad Ended	8	CoC	2003	10	.
1210	RX Date Radiation	8	CoC			R*
3180	RX Date Surg Disch	8	CoC	2003	10	.
1200	RX Date Surgery	8	CoC			R*
3230	RX Date Systemic	8	CoC	2003	10	.
720	RX Hosp--BRM	2	CoC			.
700	RX Hosp--Chemo	2	CoC			.
740	RX Hosp--DX/Stg Proc	2	CoC			.
710	RX Hosp--Hormone	2	CoC			.
730	RX Hosp--Other	1	CoC			.
3280	RX Hosp--Palliative Proc	1	CoC	2003	10	.
690	RX Hosp--Radiation	1	SEER			.
751	RX Hosp--Recon Breast	4	CoC	2024	24	.
676	RX Hosp--Reg LN Removed	2	CoC	1997	5.1	.
747	RX Hosp--Scope Reg 98-02	1	CoC			.
672	RX Hosp--Scope Reg LN Sur	1	CoC	1997	5.1	.
668	RX Hosp--Surg App 2010	1	CoC	2010	12	.
748	RX Hosp--Surg Oth 98-02	1	CoC			.
674	RX Hosp--Surg Oth Reg/Dis	1	CoC	1997	5.1	.
670	RX Hosp--Surg Prim Site 03-2022	2	CoC			.
671	RX Hosp--Surg Prim Site 2023	4	CoC	2023	23	.
746	RX Hosp--Surg Site 98-02	2	CoC			.
1410	RX Summ--BRM	2	SEER/CoC			R
1390	RX Summ--Chemo	2	SEER/CoC			R
1350	RX Summ--DX/Stg Proc	2	CoC			.
1400	RX Summ--Hormone	2	SEER/CoC			R
1420	RX Summ--Other	1	SEER/CoC			R
3270	RX Summ--Palliative Proc	1	CoC	2003	10	.
1370	RX Summ--Rad to CNS	1	SEER/CoC			.
1360	RX Summ--Radiation	1	SEER			RH
1335	RX Summ--Recon Breast	4	CoC	2024	24	.
1330	RX Summ--Reconstruct 1st	1	SEER			.
1296	RX Summ--Reg LN Examined	2	SEER/CoC	1997	5.1	.
1647	RX Summ--Scope Reg 98-02	1	SEER/CoC			.
1292	RX Summ--Scope Reg LN Sur	1	SEER/CoC	1997	5.1	R
1648	RX Summ--Surg Oth 98-02	1	SEER/CoC			.
1294	RX Summ--Surg Oth Reg/Dis	1	SEER/CoC	1997	5.1	R
1290	RX Summ--Surg Prim Site 03-2022	2	SEER/CoC	1997	5.1	RH
1291	RX Summ--Surg Prim Site 2023	4	SEER/CoC	2023	23	R
1646	RX Summ--Surg Site 98-02	2	SEER/CoC			.
1380	RX Summ--Surg/Rad Seq	1	SEER/CoC			R
1640	RX Summ--Surgery Type	2	SEER	2011	12.2	.
1310	RX Summ--Surgical Approach	1	CoC			.
1320	RX Summ--Surgical Margins	1	CoC			.
1639	RX Summ--Systemic/Sur Seq	1	CoC	2006	11	R
3250	RX Summ--Transplnt/Endocr	2	CoC	2003	10	R
1285	RX Summ--Treatment Status	1	SEER/CoC	2010	12	R#
2660	RX Text--BRM	4000	NPCR			R^
2640	RX Text--Chemo	4000	NPCR			R^
2650	RX Text--Hormone	4000	NPCR			R^
2670	RX Text--Other	4000	NPCR			R^
2620	RX Text--Radiation (Beam)	4000	NPCR			R^
2630	RX Text--Radiation Other	4000	NPCR			R^
2610	RX Text--Surgery	4000	NPCR			R^
3923	S Category Clinical	1	NAACCR	2018	18	.
3924	S Category Pathological	1	NAACCR	2018	18	.

3925	Sarcomatoid Features	3	NAACCR	2018	18	.
3926	Schema Discriminator 1	1	NAACCR	2018	18	RS
3927	Schema Discriminator 2	1	NAACCR	2018	18	RS
3928	Schema Discriminator 3	1	NAACCR	2018	18	.
3800	Schema ID	5	NAACCR	2018	18	D
2117	Schema ID Version Current	5	SEER	2021	21	D
2118	Schema ID Version Original	5	SEER	2021	21	D
3780	Secondary Diagnosis 1	7	CoC	2013	13	.
3798	Secondary Diagnosis 10	7	CoC	2013	13	.
3782	Secondary Diagnosis 2	7	CoC	2013	13	.
3784	Secondary Diagnosis 3	7	CoC	2013	13	.
3786	Secondary Diagnosis 4	7	CoC			.
3788	Secondary Diagnosis 5	7	CoC	2013	13	.
3790	Secondary Diagnosis 6	7	CoC	2013	13	.
3792	Secondary Diagnosis 7	7	CoC	2013	13	.
3794	Secondary Diagnosis 8	7	CoC	2013	13	.
3796	Secondary Diagnosis 9	7	CoC	2013	13	.
1914	SEER Cause Specific COD	1	SEER	2018	18	D
1915	SEER Other COD	1	SEER	2018	18	D
3700	SEER Site-Specific Fact 1	2	SEER	2010	12	.
3702	SEER Site-Specific Fact 2	1	SEER	2010	12	.
3704	SEER Site-Specific Fact 3	1	SEER	2010	12	.
3706	SEER Site-Specific Fact 4	1	SEER	2010	12	.
3708	SEER Site-Specific Fact 5	1	SEER	2010	12	.
3710	SEER Site-Specific Fact 6	1	SEER	2010	12	.
760	SEER Summary Stage 1977	1	SEER			RH
759	SEER Summary Stage 2000	1	SEER	2001	9	RH
834	Sentinel Lymph Nodes Examined	2	CoC	2018	18	.
835	Sentinel Lymph Nodes Positive	2	CoC	2018	18	.
3929	Separate Tumor Nodules	1	NAACCR	2018	18	.
380	Sequence Number--Central	2	SEER			R
560	Sequence Number--Hospital	2	CoC			.
3930	Serum Albumin Pretreatment Level	1	NAACCR	2018	18	.
3931	Serum Beta-2 Microglobulin Pretreatment Level	1	NAACCR	2018	18	.
220	Sex	1	SEER/CoC			R
1960	Site (73-91) ICD-O-1	4	SEER			.
450	Site Coding Sys--Current	1	NAACCR			R
460	Site Coding Sys--Original	1	NAACCR			.
2320	Social Security Number	9	SEER			R
190	Spanish/Hispanic Origin	1	SEER/CoC			R
81	State at DX Geocode 1970/80/90	2	NAACCR	2018	18	RH*
82	State at DX Geocode 2000	2	NAACCR	2018	18	D
83	State at DX Geocode 2010	2	NAACCR	2018	18	D
84	State at DX Geocode 2020	2	NAACCR	2018	18	D
1675	Subsq RX 2nd Course BRM	1	CoC	2011	12.2	.
1673	Subsq RX 2nd Course Chemo	1	CoC	2011	12.2	.
1660	Subsq RX 2nd Course Date	8	CoC			.
1674	Subsq RX 2nd Course Horm	1	CoC			.
1676	Subsq RX 2nd Course Oth	1	CoC	2011	12.2	.
1672	Subsq RX 2nd Course Rad	1	CoC	2011	12.2	.
1671	Subsq RX 2nd Course Surg	2	CoC	2011	12.2	.
1679	Subsq RX 2nd--Reg LN Rem	2	CoC	1997	5.1	.
1677	Subsq RX 2nd--Scope LN SU	1	CoC	1997	5.1	.
1678	Subsq RX 2nd--Surg Oth	1	CoC	1997	5.1	.
1695	Subsq RX 3rd Course BRM	1	CoC	2011	12.2	.
1693	Subsq RX 3rd Course Chemo	1	CoC	2011	12.2	.
1680	Subsq RX 3rd Course Date	8	CoC			.
1694	Subsq RX 3rd Course Horm	1	CoC	2011	12.2	.
1696	Subsq RX 3rd Course Oth	1	CoC	2011	12.2	.
1692	Subsq RX 3rd Course Rad	1	CoC	2011	12.2	.
1691	Subsq RX 3rd Course Surg	2	CoC	2011	12.2	.
1699	Subsq RX 3rd--Reg LN Rem	2	CoC	1997	5.1	.
1697	Subsq RX 3rd--Scope LN Su	1	CoC	1997	5.1	.
1698	Subsq RX 3rd--Surg Oth	1	CoC	1997	5.1	.
1715	Subsq RX 4th Course BRM	1	CoC	2011	12.2	.
1713	Subsq RX 4th Course Chemo	1	CoC	2011	12.2	.
1700	Subsq RX 4th Course Date	8	CoC			.
1714	Subsq RX 4th Course Horm	1	CoC	2011	12.2	.
1716	Subsq RX 4th Course Oth	1	CoC	2011	12.2	.
1712	Subsq RX 4th Course Rad	1	CoC	2011	12.2	.
1711	Subsq RX 4th Course Surg	2	CoC	2011	12.2	.
1719	Subsq RX 4th--Reg LN Rem	2	CoC	1997	5.1	.

1717	Subsq RX 4th--Scope LN Su	1	CoC	1997	5.1	.
1718	Subsq RX 4th--Surg Oth	1	CoC	1997	5.1	.
764	Summary Stage 2018	1	SEER	2018	16	R
1782	Surv-Date Active Followup	8	NAACCR	2015	15	D
1788	Surv-Date DX Recode	8	NAACCR	2015	15	D
1785	Surv-Date Presumed Alive	8	NAACCR	2015	15	D
1783	Surv-Flag Active Followup	1	NAACCR	2015	15	D
1786	Surv-Flag Presumed Alive	1	NAACCR	2015	15	D
1784	Surv-Mos Active Followup	4	NAACCR	2015	15	D
1787	Surv-Mos Presumed Alive	4	NAACCR	2015	15	D
2360	Telephone	10	SEER			.
2550	Text--DX Proc--Lab Tests	4000	NPCR			R^
2560	Text--DX Proc--Op	4000	NPCR			R^
2570	Text--DX Proc--Path	4000	NPCR			R^
2520	Text--DX Proc--PE	4000	NPCR			R^
2540	Text--DX Proc--Scopes	4000	NPCR			R^
2530	Text--DX Proc--X-ray/Scan	4000	NPCR			R^
2590	Text--Histology Title	100	NPCR			R^
2690	Text--Place of Diagnosis	60	NPCR			.
2580	Text--Primary Site Title	100	NPCR			R^
2680	Text--Remarks	4000	NPCR			.
2600	Text--Staging	4000	NPCR			R^
320	Text--Usual Industry	100	NPCR			R*
310	Text--Usual Occupation	100	NPCR			R*
3933	Thrombocytopenia	1	NAACCR	2018	18	.
980	TNM Clin Descriptor	1	CoC			.
960	TNM Clin M	4	AJCC			.
950	TNM Clin N	4	AJCC			.
970	TNM Clin Stage Group	4	AJCC			.
990	TNM Clin Staged By	2	CoC			.
940	TNM Clin T	4	AJCC			.
1060	TNM Edition Number	2	CoC			.
920	TNM Path Descriptor	1	CoC			.
900	TNM Path M	4	AJCC			.
890	TNM Path N	4	AJCC			.
910	TNM Path Stage Group	4	AJCC			.
930	TNM Path Staged By	2	CoC			.
880	TNM Path T	4	AJCC			.
344	Tobacco Use Smoking Status	1	NPCR	2022	22	R*
1148	Toronto M	3	NAACCR/SEER	2025	25	.
1147	Toronto N	3	NAACCR/SEER	2025	25	.
1149	Toronto Stage Group	3	NAACCR/SEER	2025	25	.
1146	Toronto T	3	NAACCR/SEER	2025	25	.
1135	Toronto Version Number	1	NAACCR/SEER	2025	25	.
1533	Total Dose	6	CoC	2018	18	.
3934	Tumor Deposits	2	NAACCR	2018	18	.
3935	Tumor Growth Pattern	1	NAACCR	2018	18	.
1150	Tumor Marker 1	1	SEER			.
1160	Tumor Marker 2	1	SEER			.
1170	Tumor Marker 3	1	SEER			.
60	Tumor Record Number	2	NAACCR	2011	12.2	R
752	Tumor Size Clinical	3	SEER	2016	16	.
754	Tumor Size Pathologic	3	SEER	2016	16	.
756	Tumor Size Summary	3	NPCR/CoC	2016	16	R
500	Type of Reporting Source	1	SEER			R
3936	Ulceration	1	NAACCR	2018	18	.
1850	Unusual Follow-Up Method	2	NAACCR			.
284	Urban Indian Organization (UIO)	1	NPCR	2022	22	D
285	Urban Indian Organization (UIO) Service Area	2	NPCR			D
345	URIC 2000	1	NAACCR	2018	18	D
346	URIC 2010	1	NAACCR	2018	18	D
2170	Vendor Name	10	NAACCR	2011	12.2	.
3937	Visceral and Parietal Pleural Invasion	1	NAACCR	2018	18	.
1760	Vital Status	1	SEER/CoC			R
1762	Vital Status Recode	1	NAACCR	2018	18	D
1184	White Blood Cell Count	7	NAACCR/SEER	2025	25	.

Codes for recommendations:	
.	No recommendation
D	Derived

D*	Derived, when available
R	Required
R#	Required; central registries may code available data using either SEER or CoC data items and associated rules
R*	Required, when available
R^	Required, these text requirements may be met with one or several text block fields
RC	Collected by SEER from CoC-accredited hospitals
RH	Historically collected and currently transmitted
RH*	Historically collected and currently transmitted when available
RS	Required, site specific
RS*	Required, site specific; when available
S	Supplementary/recommended